Trial Profile

Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Rivaroxaban cohort

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary)
Indications Thromboembolism
Focus Adverse reactions; Therapeutic Use
Acronyms JACRE-R
Sponsors Bayer Yakuhin

Most Recent Events

28 Sep 2017 Results assessing the effects and risks of heparin bridging and different patterns of interruption/resumption of rivaroxaban on complications of catheter ablation for atrial fibrillation ,published in the Circulation Journal
30 Aug 2017 Results a sub-analysis of JACRE Registry (n=1322; JACRE-R and JACRE-W )presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
25 Oct 2016 Results assessing safety and efficacy from Rivaroxaban cohort (JACRE-R) and Warfarin cohort (JACRE-W) studies published in the Circulation Journal.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com